Volume 30, Issue 1, July 2020, Pages 298–302
Imane Bendriss1, Z. El Mzabri2, Mounia El Youssfi3, and Samir Bargach4
1 Service de Maternité, CHP Mohamed V, Tanger, Morocco
2 Service de gynécologie, de cancérologie et de grossesse à haut risque, Maternité Souissi, Rabat, Morocco
3 Service de gynécologie obstétrique cancérologie et grossesse à haut risque, maternité Souissi, Université Mohamed V, Rabat, Morocco
4 Department of Gynecology-Obstetrics-Oncology and High-Risk Pregnancy, Souissi Maternity Hospital, Ibn Sina University Hospital Center, Rabat, Morocco
Original language: French
Copyright © 2020 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ovarian carcinosarcoma also known as mixed mesodermal tumor or mixed Mullerian tumor is a rare gynecological tumor that accounts for less than 2% of ovarian cancers. It is an aggressive tumor which combines a carcinomatous component with a sarcomatous component. In the genital tract, it most often sits in the uterus. The ovary, cervix or vagina are more rarely affected. Carcinosarcoma interests women rather between 60 and 70 years of age. The main prognostic factor found is the initial stage, most often advanced: At diagnosis, more than 90% of ovarian carcinosarcomas have an extra-ovarian extension.Surgical management is a determining factor for the survival of patients. Carcinosarcoma is an aggressive tumor, the median survival is 7 to 27 months for ovarian carcinosarcomas. Relapses mainly occur in the first year. The FIGO stage is the most important prognostic factor.Complete surgery, advanced age, the grade of the sarcomatous component and adjuvant chemotherapy are found in the rare published retrospective studies. The response rate to chemotherapy is approximately 20%.
Author Keywords: Ovarian carcinosarcoma, genital tract, initial stage, surgical management, prognostic factor, chemotherapy.
Imane Bendriss1, Z. El Mzabri2, Mounia El Youssfi3, and Samir Bargach4
1 Service de Maternité, CHP Mohamed V, Tanger, Morocco
2 Service de gynécologie, de cancérologie et de grossesse à haut risque, Maternité Souissi, Rabat, Morocco
3 Service de gynécologie obstétrique cancérologie et grossesse à haut risque, maternité Souissi, Université Mohamed V, Rabat, Morocco
4 Department of Gynecology-Obstetrics-Oncology and High-Risk Pregnancy, Souissi Maternity Hospital, Ibn Sina University Hospital Center, Rabat, Morocco
Original language: French
Copyright © 2020 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Ovarian carcinosarcoma also known as mixed mesodermal tumor or mixed Mullerian tumor is a rare gynecological tumor that accounts for less than 2% of ovarian cancers. It is an aggressive tumor which combines a carcinomatous component with a sarcomatous component. In the genital tract, it most often sits in the uterus. The ovary, cervix or vagina are more rarely affected. Carcinosarcoma interests women rather between 60 and 70 years of age. The main prognostic factor found is the initial stage, most often advanced: At diagnosis, more than 90% of ovarian carcinosarcomas have an extra-ovarian extension.Surgical management is a determining factor for the survival of patients. Carcinosarcoma is an aggressive tumor, the median survival is 7 to 27 months for ovarian carcinosarcomas. Relapses mainly occur in the first year. The FIGO stage is the most important prognostic factor.Complete surgery, advanced age, the grade of the sarcomatous component and adjuvant chemotherapy are found in the rare published retrospective studies. The response rate to chemotherapy is approximately 20%.
Author Keywords: Ovarian carcinosarcoma, genital tract, initial stage, surgical management, prognostic factor, chemotherapy.
Abstract: (french)
Le carcinosarcome ovarien appelé également tumeur mixte mésodermique ou tumeur mixte mullérienne est une tumeur gynécologique rare qui représente moins de 2% des cancers de l’ovaire. C’est une tumeur agressive qui associe une composante carcinomateuse à une composante sarcomateuse. Au niveau du tractus génital, elle siège le plus souvent au niveau de l’utérus. L’ovaire, le col ou le vagin sont plus rarement atteints. Le carcinosarcome intéresse les femmes plutôt entre 60 et 70 ans. Le facteur pronostique principal retrouvé est le stade initial, le plus souvent avancé: Au diagnostic, plus de 90% des carcinosarcomes ovariens ont une extension extra-ovarienne. La prise en charge chirurgicale est un facteur déterminant pour la survie des patientes. Le carcinosarcome est une tumeur agressive, la médiane de survie est à 7 à 27 mois pour les carcinosarcomes ovariens. Les rechutes surviennent essentiellement dans la première année. Le stade FIGO est le plus important des facteurs pronostiques. La chirurgie complète, l'âge avancé, le grade de la composante sarcomateuse et la chimiothérapie adjuvante sont retrouvés dans les rares études retrospectives publiées. Le taux de réponse à la chimiothérapie est de 20% environ.
Author Keywords: Carcinosarcome ovarien, voies génitales, stade initial, prise en charge chirurgicale, facteur pronostique, chimiothérapie.
How to Cite this Article
Imane Bendriss, Z. El Mzabri, Mounia El Youssfi, and Samir Bargach, “Carcinosarcome ovarien: A propos d’un cas,” International Journal of Innovation and Applied Studies, vol. 30, no. 1, pp. 298–302, July 2020.
